Chase Shipp
Affiliate
HDF Comprehensive Cancer Ctr
School of Medicine

Publications (4)

Top publication keywords:
HumansAgedAntibodies, MonoclonalBiomarkers, TumorMiddle AgedMaleUrinary Bladder NeoplasmsPPAR gammaGATA3 Transcription FactorUrologic NeoplasmsReceptor, ErbB-2Carcinoma, Transitional CellGene AmplificationDNA Copy Number VariationsGene Expression Regulation, Neoplastic

• HER2 overexpression in urothelial carcinoma with GATA3 and PPARG copy number gains.
  The oncologist 2024 Zhu X, Chan E, Turski ML, Mendez CE, Hsu SC, Kumar V, Shipp C, Jindal T, Chang K, Onodera C, Devine WP, Grenert JP, Stohr BA, Ding CC, Stachler MD, Quigley DA, Feng FY, Chu CE, Porten SP, Chou J, …
• Central Nervous System Disease Progression Among Patients With Metastatic Urothelial Carcinoma Treated With Enfortumab Vedotin: A Case Series.
  Clinical genitourinary cancer 2023 Shipp C, Jindal T, Chou J, Friedlander TW, Koshkin VS, Kumar V
• Somatic alterations of TP53 and MDM2 associated with response to enfortumab vedotin in patients with advanced urothelial cancer.
  Frontiers in oncology 2023 Jindal T, Zhu X, Bose R, Kumar V, Maldonado E, Deshmukh P, Shipp C, Feng S, Johnson MS, Angelidakis A, Kwon D, Borno HT, de Kouchkovsky I, Desai A, Aggarwal R, Fong L, Small EJ, Wong A, Porten S, Chou…
• Diastereoselective Synthesis of P-Stereogenic Secondary Phosphine Oxides (SPOs) Bearing a Chiral Substituent by Ring Opening of (+)-Limonene Oxide with Primary Phosphido Nucleophiles.
  The Journal of organic chemistry 2020 Zimmerman AN, Xu RS, Reynolds SC, Shipp CA, Marshall DJ, Wang G, Blank NF, Gibbons SK, Hughes RP, Glueck DS, Balaich GJ, Rheingold AL